I · THE FRONTIER

The brain is
medicine's last frontier.

Where serious disease begins, and where existing therapies still fall short.
SCROLL
AXIARA·THERAPEUTICS
INITIALIZING…
THE OPPORTUNITY

Millions live with brain disorders that modern medicine has not solved.

Axiara Therapeutics is a discovery-stage CNS drug discovery company building a pipeline of first-in-class, small-molecule medicines for conditions where existing therapies fall short and the underlying circuit dysfunction goes unaddressed.

Millions
Patients underserved
Inadequately served by existing therapies despite decades of advances in modern medicine.
>$100B
Market opportunity
Across multiple CNS therapeutic areas defined by significant unmet medical need.
First-in-Class
The innovation gap
Differentiated biological mechanisms with the potential to enable entirely new treatments.
Validated
The evidence base
Independent evidence across multiple research groups supports the biological mechanisms underlying our pipeline.
OUR APPROACH

We don't screen broadly.
We understand the biology first.

Deep Target Biology

Every program begins with mechanistic insight, how small molecules engage a specific binding site, how that engagement translates to functional modulation, and how it maps to disease-relevant circuits.

Chemistry Driven by Mechanism

Medicinal chemistry guided by structural and functional data. Compound design is informed by direct knowledge of target pharmacology, binding-site architecture, and selectivity, not empirical screening.

Academic Partnerships & Licensed IP

Exclusive licenses to intellectual property from leading research universities, backed by a network spanning electrophysiology, structural pharmacology, computational chemistry, and in vivo pharmacology.

DISCOVERY PORTFOLIO

A diversified portfolio of proprietary
small-molecule programs.

Spanning multiple therapeutic areas and stages of discovery, each advancing scientifically validated biology toward optimized, proprietary development candidates.

Program
Therapeutic Area
Stage
Program Alpha
Neurological Disorders
Lead Optimization
Program Beta
Sensory Disorders
Hit to Lead
Program Gamma
Psychiatric Disorders
Hit to Lead
Program Delta
Peripheral Disorders
Hit to Lead
Program Epsilon
Exploratory Biology
Discovery
WHY AXIARA SUCCEEDS

Translating well-characterized science into medicines.

01Target Insight

Programs built around targets where the team has direct, molecular-level knowledge of engagement, selectivity across subtypes, and therapeutic effect in disease models. A rare foundation and a real competitive edge.

02Validated Biology

Every program is supported by published, peer-reviewed data demonstrating target relevance in disease, replicated across independent groups in cellular and in vivo models. Not a bet on unvalidated biology.

03Execution Capability

Deep drug-discovery expertise paired with experienced biotech and translational leadership. A lean structure, licensed IP, and existing data package direct capital straight into program advancement.

04Scientific Foundation

Programs grounded in peer-reviewed research published in leading journals, with founders and collaborators who characterized the molecular pharmacology and therapeutic relevance of the target class.

CONTACT

From molecule to medicine,
for the brain's hardest problems.

Axiara Therapeutics · Cambridge, Massachusetts

GET IN TOUCH · info@axiaratx.com